Article Text

Download PDFPDF
CASE REPORT
Abciximab-induced delayed profound thrombocytopaenia
  1. Manar Jbara1,
  2. Sukhdeep Bhogal1,
  3. Kailash Bajaj2,
  4. Lovely Chhabra3
  1. 1Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, USA
  2. 2East Tennessee State University, Kingsport, Tennessee, USA
  3. 3Hartford Hospital, University of Connecticut School of Medicine, Hartford, Connecticut, USA
  1. Correspondence to Professor Kailash Bajaj, BAJAJK{at}mail.etsu.edu

Summary

Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.

  • Cardiovascular system
  • Safety
  • Unwanted effects / adverse reactions
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors MJ and SB were responsible for the manuscript preparation, writing and data collection. KB and LC were responsible for the revision and critique review of the article.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.